How has the new WHO (5th edition and ICC classification scheme for MDS impacted our understanding and management, particularly in distinguishing lower and higher risk categories?
How has our understanding of the molecular landscape of MDS evolved, and how does this knowledge inform personalized treatment approaches?
The 2026 meeting in Denver features more than 265 hours of programming, real-world MASH treatment data, and late-breaking results in rare liver diseases.
A cranberry supplement was tied to greater OAB symptom score reductions than placebo in a 25-woman pilot trial, but urobiome findings were unconfirmed.
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
In an insured population with advanced lung cancer, clinical trial participants had lower or similar total health care costs compared with nonparticipants.